No Data
No Data
Otsuka Holdings' Attributable Profit Soars 26% in Fiscal Q1
Otsuka Holdings' (TYO:4578) profit attributable to owners of the parent soared 26% to 77.4 billion yen in the fiscal first quarter ended March 31, from 61.4 billion yen a year ago mainly due to increa
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
Monday, Esperion Therapeutics (NASDAQ:ESPR) and Otsuka Pharmaceutical Co Ltd announced that the primary endpoint in the Phase 3 trial in Japan for bempedoic acid for hypercholesterolemia was achieved.
Esperion, Otsuka Report Primary Endpoint Was Achieved In Phase 3 Trial In Japan For Bempedoic Acid As Potential Treatment For Patients With Hypercholesterolemia
The trial demonstrated statistically significant outcomes on the primary endpoint for bempedoic acid and highlighted its potential future value to patients in Japan.In the preliminary results, the per
Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide
FRANKFURT, GERMANY and PALO ALTO, Calif., May 17, 2024 /PRNewswire/ -- Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwi
Recor Medical Soutient Des Actions Mondiales À L'occasion De La Journée Mondiale De L'hypertension : L'intervention Précoce Et L'innovation Continue Sont Les Clés De La Lutte Contre Ce Tueur Silencieux Qui Affecte Des Milliards De Personnes Dans...
Recor Medical Soutient Des Actions Mondiales À L'occasion De La Journée Mondiale De L'hypertension : L'intervention Précoce Et L'innovation Continue Sont Les Clés De La Lutte Contre Ce Tueur Silen
Otsuka: Confirmation
No Data